Company

FDA Flags Potential NAION Vision‑Loss Risk with GLP‑1 RA Medications – Labeling Update Required Across the Drug Class
Hot targets

FDA Flags Potential NAION Vision‑Loss Risk with GLP‑1 RA Medications – Labeling Update Required Across the Drug Class

The U.S. Food and Drug Administration (FDA) announced it is informing patients and health care providers of a potential increased risk of non‑arteritic anterior ischemic optic neuropathy (NAION) associated with…

Revvity and BioMap Sign Strategic AI4S Partnership – A "Dry‑Wet" Closed‑Loop Alliance to Accelerate AI‑Empowered Life Sciences

Revvity and BioMap Sign Strategic AI4S Partnership – A “Dry‑Wet” Closed‑Loop Alliance to Accelerate AI‑Empowered Life Sciences

Lepu Medical's Minwei Biotech Secures NMPA Clinical Trial Approval for MWX205 – World's First PCSK9/ANGPTL3 Dual‑Target siRNA for Dyslipidemia

Lepu Medical’s Minwei Biotech Secures NMPA Clinical Trial Approval for MWX205 – World’s First PCSK9/ANGPTL3 Dual‑Target siRNA for Dyslipidemia

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
NMPA Approves Lynparza as Adjuvant Treatment for High-Risk Breast Cancer Patients
AstraZenecaAZ

NMPA Approves Lynparza as Adjuvant Treatment for High-Risk Breast Cancer Patients

Gilead Sciences' Sunlenca Receives NMPA Approval for Multidrug-Resistant HIV-1 Infection
Gilead SciencesHIV / AIDS care

Gilead Sciences’ Sunlenca Receives NMPA Approval for Multidrug-Resistant HIV-1 Infection

WinHealth Pharma's Difelikefalin Receives NMPA Review for Market Approval
Market approval filingsWinHealth Pharma

WinHealth Pharma’s Difelikefalin Receives NMPA Review for Market Approval

Thederma's TAN-118 Receives Tacit Clinical Approval from China's CDE for Global Trials
Clinical trial approval / initiationGastroenterology

Thederma’s TAN-118 Receives Tacit Clinical Approval from China’s CDE for Global Trials

Show More